Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Urinary incontinence means losing control of bladder due to which there is an involuntary leakage of urine. In this condition, control over the urinary sphincter is weakened or completely lost and due to this, a person urinates even when they do not want to. This is a very common and often embarrassing problem for people. At the time of urination, muscles around urethra relax and let urine pass out of the body, however, in urinary incontinence, muscles around urethra do not work in the way they should, resulting in leak-out of urine. There are various type of incontinences such as stress (bladder is under pressure), urge (intense urge to pass urine), and overflow (chronic urinary retention). The severity of urinary incontinence varies as per health conditions such as urinary tract infection (UTI), constipation, and age group, as urinary incontinence is found more in geriatric population.
The global urinary incontinence treatment drugs market is estimated to be valued at US$ 4,180.6 million in 2020 and is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027).
Figure 1. Global Urinary Incontinence Treatment Drugs Market Share (%) Analysis, By Region, 2020
Increasing number of regulatory approval for drugs is driving growth of the global urinary incontinence treatment drugs market
For instance, in 2018, Astellas Pharma Inc. received the U.S. Food and Drug Administration approval for its supplemental new drug application (sNDA) for the use of mirabegron in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence.
For instance, in 2016, Cipla Limited = received Abbreviated New Drug Application (ANDA) for Darifenacin extended-release tablets from the U. S. Food and Drug Administration (FDA) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Urinary Incontinence Treatment Drugs Market Report Coverage
||Market Size in 2020:
||US$ 4,180.6 Mn
|Historical Data for:
||2017 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 5,427.7 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Incontinence Type: Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, Other Type.
- By Drug Class: Anticholinergic/Antispasmodic agents, Skeletal muscle Relaxants, Antidepressants, Alpha blockers, Topical estrogens, Others.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
- Increasing number of regulatory approval of drugs
- Increasing prevalence of urinary incontinence disease
|Restraints & Challenges:
Urinary Incontinence Treatment Drugs Market- Restraints
Unfavorable side effects such as constipation, dry skin, dry eyes, and upset stomach, low efficacy of available drug and difficulty in disease diagnosis, and negligence about urinary incontinence disorders are the major restraining factors for the urinary incontinence treatment drugs market growth.
Urinary Incontinence Treatment Drugs Market– Regional Analysis
North America accounted for the largest share in the urinary incontinence treatment drugs market, owing to increasing prevalence of overactive bladder. For instance, according to Urology Care Foundation 2019 report, it is estimated that 30% of men and 40% of women in the U.S. live with overactive bladder (OVB).
Furthermore, Asia Pacific is expected to observe the fastest growth during the forecast period, owing to increasing approval of drugs by regulatory authorities. For instance, in September 2018, Kissei Pharmaceutical Co., Ltd. and KYORIN Holdings, Inc. jointly announced that KYORIN Pharmaceutical Co., Ltd., a wholly owned subsidiary of KYORIN Holdings, Inc., received approval from the Ministry of Health, Labour and Welfare for the treatment of overactive bladder in Japan.
Figure 2. Urinary Incontinence Treatment Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Urinary Incontinence Treatment Drugs Market- Competitive Landscape
Key players operating in the urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.